The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 198K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oravecz, T.
Right arrow Articles by Norcross, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oravecz, T.
Right arrow Articles by Norcross, M. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1997/12/1865/ $5.00
The Journal of Experimental Medicine, Volume 186, Number 11, December 1, 1997 1865-1872


Articles

Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated Cleavage

Tamas Oravecz*, Marina Pall*, Gregory Roderiquez*, Mark D. Gorrell||, Mary Ditto*, Nga Y. Nguyen§, Robert Boykins{ddagger}, Edward Unsworth§, and Michael A. Norcross*

From the * Division of Hematologic Products, {ddagger} Division of Allergenics Products and Parasitology, and § Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892; and || A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital and University of Sydney, Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales 2042, Australia

CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV activity but whose natural substrates and immunological functions have not been clearly defined. Several chemo-kines, including RANTES (regulated on activation, normal T cell expressed and secreted), have now been shown to be substrates for recombinant soluble human CD26. The truncated RANTES(3–68) lacked the ability of native RANTES(1–68) to increase the cytosolic calcium concentration in human monocytes, but still induced this response in macrophages activated with macrophage colony-stimulating factor. Analysis of chemokine receptor messenger RNAs and patterns of desensitization of chemokine responses showed that the differential activity of the truncated molecule results from an altered receptor specificity. RANTES(3–68) showed a reduced activity, relative to that of RANTES(1–68), with cells expressing the recombinant CCR1 chemokine receptor, but retained the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. Our results indicate that CD26-mediated processing together with cell activation–induced changes in receptor expression provides an integrated mechanism for differential cell recruitment and for the regulation of target cell specificity of RANTES, and possibly other chemokines.


Address correspondence to Michael A. Norcross or Tamas Oravecz, Division of Hematologic Products, Center for Biologics Evaluation and Research, FDA, NIH, Bldg 29B, Rm 4E12, HFM-541, Bethesda, MD 20892. Phone: 301-827-0793; FAX: 301-480-3256; E-mail: miken{at}helix.nih.gov or tamas{at}helix.nih.gov

Note added in proof. We note that a CD8+ T cell–derived HIV-1 suppressor activity has been recently identified as a truncated form of macrophage-derived chemokine (MDC), missing a glycine–proline dipeptide from the NH2 terminus (Pal, R., A. Garzino-Demo, P.D. Markham, J. Burns, M. Brown, R.C. Gallo, and A.L. DeVico. 1997. Science. 278:695–698). Based on our results, we suggest that truncation of MDC is a consequence of CD26-mediated cleavage that may have resulted in enhanced MDC antiviral activity.

1 Abbreviations used in this paper: [Ca2+]i, cytosolic free Ca2+ concentration; DPPIV, dipeptidyl peptidase IV; E+, enzymatically active; E, enzymatically deficient; ES-MS, electrospray mass spectrometry; GAPDH, glyceraldehyde phosphate dehydrogenase; HEK, human embryonic kidney; HOS, human osteosarcoma; IP, interferon-{gamma}-inducible protein; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; pNA, p-nitroanilide; RANTES, regulated on activation, normal T cell expressed and secreted; rh, recombinant human; s, soluble; SDF, stromal-derived factor.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS